Cells · 2019 · 12 citations · 55 references
Life SciencesNeurologyNeuroscienceClinical NeuroscienceNeurobiology Of DiseaseNeurodegenerationDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic PathophysiologyAnimal Disease ModelsBrain RegionsCorpus Callosum AbnormalitiesDemyelination PathophysiologyMultiple Sclerosis ModelsMultiple Sclerosis NeuroprotectionRegional Brain MetabolismSubcortical Structures
Brain volume measurement is one of the most frequently used biomarkers to establish neuroprotective effects during pre-clinical multiple sclerosis (MS) studies. Furthermore, whole-brain atrophy estimates in MS correlate more robustly with clinical disability than traditional, lesion-based metrics. However, the underlying mechanisms leading to brain atrophy are poorly understood, partly due to the lack of appropriate animal models to study this aspect of the disease. The purpose of this study was to assess brain volumes and neuro-axonal degeneration after acute and chronic cuprizone-induced demyelination. C57BL/6 male mice were intoxicated with cuprizone for up to 12 weeks. Brain volume, as well as total numbers and densities of neurons, were determined using design-based stereology. After five weeks of cuprizone intoxication, despite severe demyelination, brain volumes were not altered at this time point. After 12 weeks of cuprizone intoxication, a significant volume reduction was found in the corpus callosum and diverse subcortical areas, particularly the internal capsule and the thalamus. Thalamic volume loss was accompanied by glucose hypermetabolism, analyzed by [18F]-fluoro-2-deoxy-d-glucose (18F-FDG) positron-emission tomography. This study demonstrates region-specific brain atrophy of different subcortical brain regions after chronic cuprizone-induced demyelination. The chronic cuprizone demyelination model in male mice is, thus, a useful tool to study the underlying mechanisms of subcortical brain atrophy and to investigate the effectiveness of therapeutic interventions.
55
Axonal Transection in the Lesions of Multiple Sclerosis
Bruce D. Trapp, John W. Peterson, Richard M. Ransohoff et al. · New England Journal of Medicine · 1998 · 4K citations · Full text
Gray matter atrophy in multiple sclerosis: A longitudinal study
Elizabeth Fisher, Jar‐Chi Lee, Kunio Nakamura et al. · Annals of Neurology · 2008 · 673 citations
Thalamic atrophy and cognition in multiple sclerosis
Maria K. Houtchens, Ralph H. B. Benedict, Ronald Killiany et al. · Neurology · 2007 · 495 citations